Matt Sause to become new CEO of Roche Diagnostics
Basel: Roche has announced that Matt Sause, currently Head of Roche Diagnostics' North America Region, will become CEO of Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
Thomas Schinecker, the incumbent CEO of the Diagnostics Division and new Roche CEO as of 15 March 2023 said, "Matt Sause's career at Roche has spanned twenty years in multiple countries across Asia, Latin America, Europe and North America in both the Diagnostics and Pharma divisions. His combination of scientific knowledge with commercial experience makes him an excellent leader for the Diagnostics division."
Severin Schwan, currently Roche CEO, who has been proposed by the Roche Board of Directors as the new Chairman of Roche at the Annual General Meeting on 14 March 2023 said, "Matt Sause has had an exceptional career with Roche and I am very pleased that we can once again internally appoint a leader of his caliber to become the next CEO Roche Diagnostics".
Matt began his career with Roche in the United States in 2002 as a Senior Molecular Account Manager and progressed in various commercial general management and global product leadership roles spanning both the Diagnostics and Pharma divisions in multiple countries such as Japan, Ireland, Peru, and South Korea.
In 2018, he moved to Genentech in the United States to become Lifecycle Leader for Tecentriq Lung and Head and Neck Cancers before eventually taking over his current role as President and CEO for Roche Diagnostics North America. Matt holds a Bachelor's degree in Microbiology from Miami University and an MBA from University of California, San Diego.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Read also: Bayer, Regeneron anti-blindness drug Eylea shown to work at higher dose, longer intervals
